John completed his PhD in molecular recognition in 1995. He moved into commercial pharmaceutical R&D and from there in 1998 to a lectureship position in TCD. John has a wide range of interests in drug development including drug targeting and bile acid medicinal chemistry. John has numerous patent filings and has published widely in pharmaceutical sciences. He is a cofounder of Solvotrin Therapeutics which is developing new prodrug and related delivery technologies. John leads the module on regulatory affairs and industrial pharmacy.